Ccl21 and checkpoint inhibitors for the treatment of cancer
AssigneesThe Regents of the University of California, The United States Government as represented by the Department of Veterans Affairs
InventorsSteven M. DUBINETT, Jay Moon LEE, Bin LIU, Ramin SALEHI-RAD, Sharvendra SHARMA
Life of this patent
Estimating the term…
Abstract
The present disclosure relates, in general, to methods for treating cancer comprising administering to a subject in need thereof an effective amount of dendritic cells comprising the human CCL21 gene in combination with an anti-PD-1 antibody. In one aspect, the treatment is amenable to patients with tumors having a high mutational burden.
Claims25
A method of treating cancer or a solid tumor having a high mutational burden in a subject comprising
- a. administering to the subject (i) a SLC polypeptide, (ii) a polynucleotide encoding the SLC polypeptide, (iii) a cell comprising the polynucleotide encoding the SLC polypeptide, or (iv) any combination thereof, and
- b. administering to the subject an immune checkpoint inhibitor.
14-15. (canceled)
18-23. (canceled)
25-54. (canceled)
The method of claim 83, wherein the cancer is a high mutational burden cancer.
57-82. (canceled)
A method for treating cancer or reducing the recurrence of cancer in a subject in need thereof comprising administering an effective amount of a combination therapy comprising a) dendritic cells comprising a vector-CCL21 (vector-CCL21-DC) construct on days 0, 21, and 42, and b) an effective amount of anti-PD-1 antibody every three weeks starting on day 0, optionally wherein the vector is an adenoviral vector (Ad-CCL21-DC).
85-102. (canceled)
Dependencies are inferred from the claim text.